Serotonin and dreaming

Serotonin and Sleep: Molecular, Functional and Clinical Aspects

Volumn , Issue , 2008, Pages 307-324

  Pace Schott, Edward F ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84873427380     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-7643-8561-3_12     Document Type: Chapter

References (114)

1. Perry E, Ashton H, Young A (2002) Neurochemistry of consciousness: Transmitters in mind. John Benjamins Publishing Company, Amsterdam
2. Pace-Schott EF (2005) The neurobiology of dreaming. In: MH Kryger, T Roth, WC Dement (eds): Principles and practice of sleep medicine, 4th edn. Elsevier, Philadelphia, 551-572
3. Hobson JA, Pace-Schott EF, Stickgold R (2000) Dreaming and the brain: toward a cognitive neuroscience of conscious states. Behav Brain Sci 23: 793-842; discussion 904-1121
4. Thompson DF, Pierce DR (1999) Drug-induced nightmares. Ann Pharmacother 33: 93-98
5. Pagel JF, Helfter P (2003) Drug induced nightmares-An etiology based review. Hum Psychopharmacol 18: 59-67
6. Pagel J (2004) Drug induced alterations in dreaming: An exploration of the dream data terrain outside activation-synthesis. Behav Brain Sci 27: 702-707
7. Markowitz JC (1991) Fluoxetine and dreaming. J Clin Psychiatry 52: 432
8. Lepkifker E, Dannon PN, Iancu I, Ziv R, Kotler M (1995) Nightmares related to fluoxetine treatment. Clin Neuropharmacol 18: 90-94
9. Pace-Schott EF, Gersh T, Silvestri R, Stickgold R, Salzman C, Hobson JA (2001) SSRI treatment suppresses dream recall frequency but increases subjective dream intensity in normal subjects. J Sleep Res 10: 129-142
10. Gottesmann C (2002) Dreaming: Monoaminergic disinhibition hypothesis. In: E Perry, H Ashton, A Young (eds): Neurochemistry of consciousness: Transmitters in Mind. John Benjamins, Amsterdam, 133-146
11. Solms M (2002) Dreaming: cholinergic and dopaminergic hypotheses. In: E Perry, H Ashton, A Young (eds): Neurochemistry of consciousness: Transmitters in mind. John Benjamin, Amsterdam, 123-131
12. Gottesmann C (2006) The dreaming sleep stage: A new neurobiological model of schizophrenia? Neuroscience 140: 1105-1115
13. Pace-Schott EF (2003) Recent findings on the neurobiology of sleep and dreaming. In: EF Pace-Schott, M Solms, M Blagrove, S Harnad (eds): Sleep and dreaming: Scientific advances and reconsiderations. Cambridge University Press, Cambridge
14. Pace-Schott EF, Hobson JA, Stickgold R (1994) The fluoxetine-mediated increase in NREM eye movements can be detected in the home setting using the Nightcap. Sleep Res 23: 459
15. Armitage R, Rochlen A, Fitch T, Trivedi M, Rush J (1995) Dream recall and major depression: A preliminary report. Dreaming 5: 189-198
16. Koponen H, Lepola U, Leinonen E, Jokinen R, Penttinen J, Turtonen J (1997) Citalopram in the treatment of obsessive-compulsive disorder: an open pilot study. Acta Psychiatr Scand 96: 343-346
17. Kirschner NT (1999) Medication and dreams: Changes in dream content after drug treatment. Dreaming 9: 195-200
18. Ebben M, Lequerica A, Spielman A (2002) Effects of pyridoxine on dreaming: A preliminary study. Percept Mot Skills 94: 135-140
19. Devulder J, De Laat M, Dumoulin K, Renson A, Rolly G (1996) Nightmares and hallucinations after long-term intake of tramadol combined with antidepressants. Acta Clin Belg 51: 184-186
20. Radbruch L, Grond S, Lehmann KA (1996) A risk-benefit assessment of tramadol in the management of pain. Drug Saf 15: 8-29
21. Neylan TC, Metzler TJ, Schoenfeld FB, Weiss DS, Lenoci M, Best SR, Lipsey TL, Marmar CR (2001) Fluvoxamine and sleep disturbances in posttraumatic stress disorder. J Trauma Stress 14: 461-467
22. Berger M, Riemann D (1993) Symposium: Normal and abnormal REM sleep regulation: REM sleep in depression-an overview. J Sleep Res 2: 211-223
23. Riemann D, Low H, Schredl M, Wiegand M, Dippel B, Berger M (1990) Investigations of morning and laboratory dream recall and content in depressive patients during baseline conditions and under antidepressive treatment with trimipramine. Psychiatr J Univ Ott 15: 93-99
24. Antrobus JS, Schnee RK, Lynne A, Silverman SS, Offer V, Boback P (1977) Psycholinguistic coding manual for reports of sleep and stimulus independent waking state experience. Educational Testing Service Princeton
25. Maher EA (1997) Bizarrenesss and fictive movement in Nightcap mentation reports: Implications for activation-synthesis theory: Psychology. Harvard University Extension School, Boston
26. Williams J, Merritt J, Rittenhouse C, Hobson JA (1992) Bizarreness in dreams and fantasies: Implications for the activation-synthesis hypothesis. Consciousness Cognition 1: 172-185
27. Ajilore O, Stickgold R, Rittenhouse CD, Hobson JA (1995) Nightcap: laboratory and home-based evaluation of a portable sleep monitor. Psychophysiology 32: 92-98
28. Silvestri R, Pace-Schott EF, Gersh T, Stickgold R, Salzman C, Hobson JA (2001) Effects of fluvoxamine and paroxetine on sleep structure in normal subjects: A homebased Nightcap evaluation during drug administration and withdrawal. J Clin Psychiatry 62: 642-652
29. Armitage R (1996) Effects of antidepressant treatment on sleep EEG in depression. J Psychopharmacol 10: 22-25
30. Dorsey CM, Lukas SE, Cunningham SL (1996) Fluoxetine-induced sleep disturbance in depressed patients. Neuropsychopharmacology 14: 437-442
31. Kupfer DJ, Perel JM, Pollock BG, Nathan RS, Grochocinski VJ, Wilson MJ, McEachran AB (1991) Fluvoxamine versus desipramine: comparative polysomnographic effects. Biol Psychiatry 29: 23-40
32. Mayers AG, Baldwin DS (2005) Antidepressants and their effect on sleep. Hum Psychopharmacol 20: 533-559
33. Oberndorfer S, Saletu-Zyhlarz G, Saletu B (2000) Effects of selective serotonin reuptake inhibitors on objective and subjective sleep quality. Neuropsychobiology 42: 69-81
34. Thase ME (1998) Depression, sleep, and antidepressants. J Clin Psychiatry 59 Suppl 4: 55-65
35. Oswald I, Adam K (1986) Effects of paroxetine on human sleep. Br J Clin Pharmacol 22: 97-99
36. Saletu B, Frey R, Krupka M, Anderer P, Grunberger J, See WR (1991) Sleep laboratory studies on the single-dose effects of serotonin reuptake inhibitors paroxetine and fluoxetine on human sleep and awakening qualities. Sleep 14: 439-447
37. Armitage R, Trivedi M, Rush J, Hoffman R (1995) The effects of fluoxetine on periodanalyzed sleep EEG in depression. Sleep Res 24: 381
38. Armitage R, Trivedi M, Rush AJ (1995) Fluoxetine and oculomotor activity during sleep in depressed patients. Neuropsychopharmacology 12: 159-165
39. Hendrickse WA, Roffwarg HP, Grannemann BD, Orsulak PJ, Armitage R, Cain JW, Battaglia J, Debus JR, Rush AJ (1994) The effects of fluoxetine on the polysomnogram of depressed outpatients: A pilot study. Neuropsychopharmacology 10: 85-91
40. Dorsey CM, Lukas SE, Cunningham SL, Richardson GS, Winkelman JW (1992) Increased risk of periodic leg movements during sleep with use of fluoxetine. Sleep Res 21: 56
41. Schenck CH, Mahowald MW, Kim SW, O'Connor KA, Hurwitz TD (1992) Prominent eye movements during NREM sleep and REM sleep behavior disorder associated with fluoxetine treatment of depression and obsessive-compulsive disorder. Sleep 15: 226-235
42. Ellison JM, Stanziani P (1993) SSRI-associated nocturnal bruxism in four patients. J Clin Psychiatry 54: 432-434
43. Armitage R, Trivedi M, Rush J, Pechacek P, Cole D, Dunnam D (1994) Effects of fluoxetine on EOG and EMG activity during sleep in depression. Sleep Res 23: 61
44. Dorsey CM, Cunningham SL, Lukas SE, Winkelman JW, Richardson GS, Jones K (1992) Fluoxetine-induced eye movements during non-REM sleep. Sleep Res 21: 55
45. Geyer JD, Carney PR, J. P, Parrish P (2006) Anti-depressant medications, neuroleptics and prominent eye movements during NREM sleep. Sleep 29: A34
46. Gagnon JF, Postuma RB, Montplaisir J (2006) Update on the pharmacology of REM sleep behavior disorder. Neurology 67: 742-747
47. Coupland NJ, Bell CJ, Potokar JP (1996) Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 16: 356-362
48. Dilsaver SC (1994) Withdrawal phenomena associated with antidepressant and antipsychotic agents. Drug Saf 10: 103-114
49. Trivedi MH, Rush AJ, Armitage R, Gullion CM, Grannemann BD, Orsulak PJ, Roffwarg HP (1999) Effects of fluoxetine on the polysomnogram in outpatients with major depression. Neuropsychopharmacology 20: 447-459
50. DeVane CL (1992) Pharmacokinetics of the selective serotonin reuptake inhibitors. J Clin Psychiatry 53 Suppl: 13-20
51. Manfridi RL, Kales A (1987) Clinical neuropharmacology of sleep disorders. Semin Neurol 7: 286-295
52. McCarley RW, Hobson JA (1975) Neuronal excitability modulation over the sleep cycle: A structural and mathematical model. Science 189: 58-60
53. Berger M, Riemann D, Hochli D, Spiegel R (1989) The cholinergic rapid eye movement sleep induction test with RS-86. State or trait marker of depression? Arch Gen Psychiatry 46: 421-428
54. Gillin JC, Sutton L, Ruiz C, Kelsoe J, Dupont RM, Darko D, Risch SC, Golshan S, Janowsky D (1991) The cholinergic rapid eye movement induction test with arecoline in depression. Arch Gen Psychiatry 48: 264-270
55. Sitaram N, Moore AM, Gillin JC (1978) Experimental acceleration and slowing of REM sleep ultradian rhythm by cholinergic agonist and antagonist. Nature 274: 490-492
56. Sitaram N, Wyatt RJ, Dawson S, Gillin JC (1976) REM sleep induction by physostigmine infusion during sleep. Science 191: 1281-1283
57. Sitaram N, Moore AM, Gillin JC (1978) The effect of physostigmine on normal human sleep and dreaming. Arch Gen Psychiatry 35: 1239-1243
58. Vogel GW, Buffenstein A, Minter K, Hennessey A (1990) Drug effects on REM sleep and on endogenous depression. Neurosci Biobehav Rev 14: 49-63
59. Sharpley AL, Cowen PJ (1995) Effect of pharmacologic treatments on the sleep of depressed patients. Biol Psychiatry 37: 85-98
60. Hobson JA, McCarley RW (1977) The brain as a dream state generator: an activationsynthesis hypothesis of the dream process. Am J Psychiatry 134: 1335-1348
61. Page F, Coleman G, Conduit R (2006) The effect of transdermal nicotine patches on sleep and dreams. Physiol Behav 88: 425-432
62. Lam S, Patel PN (2007) Varenicline: A selective alpha4beta2 nicotinic acetylcholine receptor partial agonist approved for smoking cessation. Cardiol Rev 15: 154-161
63. Kitabayashi Y, Ueda H, Tsuchida H, Yamashita T, Narumoto J, Fukui K (2006) Donepezil-induced nightmares in mild cognitive impairment. Psychiatry Clin Neurosci 60: 123-124
64. Ross JS, Shua-Haim JR (1998) Aricept-induced nightmares in Alzheimer's disease:
65. case reports. J Am Geriatr Soc 46: 119-120
66. Singer M, Romero B, Koenig E, Forstl H, Brunner H (2005) [Nightmares in patients with Alzheimer's disease caused by donepezil. Therapeutic effect depends on the time of intake]. Nervenarzt 76: 1127-1128, 1129
67. Yamada Y, Shibuya F, Hamada J, Sawada Y, Iga T (1995) Prediction of sleep disorders induced by beta-adrenergic receptor blocking agents based on receptor occupancy. J Pharmacokinet Biopharm 23: 131-145
68. Adrien J (2002) Neurobiological bases for the relation between sleep and depression. Sleep Med Rev 6: 341-351
69. Landolt HP, de Boer LP (2001) Effect of chronic phenelzine treatment on REM sleep: report of three patients. Neuropsychopharmacology 25: S63-67
70. Landolt HP, Raimo EB, Schnierow BJ, Kelsoe JR, Rapaport MH, Gillin JC (2001) Sleep and sleep electroencephalogram in depressed patients treated with phenelzine. Arch Gen Psychiatry 58: 268-276
71. Wilson S, Argyropoulos S (2005) Antidepressants and sleep: A qualitative review of the literature. Drugs 65: 927-947
72. Adam K, Oswald I (1989) Effects of repeated ritanserin on middle-aged poor sleepers. Psychopharmacology (Berl) 99: 219-221
73. Idzikowski C, Mills FJ, James RJ (1991) A dose-response study examining the effects of ritanserin on human slow wave sleep. Br J Clin Pharmacol 31: 193-196
74. Idzikowski C, Mills FJ, Glennard R (1986) 5-Hydroxytryptamine-2 antagonist increases human slow wave sleep. Brain Res 378: 164-168
75. Mayer G (2003) Ritanserin improves sleep quality in narcolepsy. Pharmacopsychiatry 36: 150-155
76. Monti JM (1987) Disturbances of sleep and wakefulness associated with the use of antihypertensive agents. Life Sci 41: 1979-1988
77. Sharpley AL, Elliott JM, Attenburrow MJ, Cowen PJ (1994) Slow wave sleep in humans: role of 5-HT2A and 5-HT2C receptors. Neuropharmacology 33: 467-471
78. Sharpley AL, Solomon RA, Fernando AI, da Roza Davis JM, Cowen PJ (1990) Doserelated effects of selective 5-HT2 receptor antagonists on slow wave sleep in humans. Psychopharmacology (Berl) 101: 568-569
79. van Laar M, Volkerts E, Verbaten M (2001) Subchronic effects of the GABA-agonist lorazepam and the 5-HT2A/2C antagonist ritanserin on driving performance, slow wave sleep and daytime sleepiness in healthy volunteers. Psychopharmacology (Berl) 154: 189-197
80. Landolt HP, Meier V, Burgess HJ, Finelli LA, Cattelin F, Achermann P, Borbely AA (1999) Serotonin-2 receptors and human sleep: effect of a selective antagonist on EEG power spectra. Neuropsychopharmacology 21: 455-466
81. Hobson JA (1999) Dreaming as delirium. MIT Press, Cambridge
82. Hobson JA (2001) The dream drug store. MIT Press, Cambridge
83. Aghajanian GK, Marek GJ (1999) Serotonin and hallucinogens. Neuropsychopharmacology 21: 16S-23S
84. Derry C, Benjamin C, Bladin P, le Bars D, Tochon-Danguy H, Berkovic SF, Zimmer L, Costes N, Mulligan R, Reutens D (2006) Increased serotonin receptor availability in human sleep: evidence from an [18F]MPPF PET study in narcolepsy. Neuroimage 30: 341-348
85. Zeitzer JM, Maidment NT, Behnke EJ, Ackerson LC, Fried I, Engel J Jr, Wilson CL (2002) Ultradian sleep-cycle variation of serotonin in the human lateral ventricle. Neurology 59: 1272-1274
86. Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX (2004) Acute psychological and physiological effects of psilocybin in healthy humans: A double-blind, placebocontrolled dose-effect study. Psychopharmacology (Berl) 172: 145-156
87. Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J (1997) Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 16: 357-372
88. Nofzinger EA, Mintun MA, Wiseman M, Kupfer DJ, Moore RY (1997) Forebrain activation in REM sleep: an FDG PET study. Brain Res 770: 192-201
89. Maquet P, Peters J, Aerts J, Delfiore G, Degueldre C, Luxen A, Franck G (1996) Functional neuroanatomy of human rapid-eye-movement sleep and dreaming. Nature 383: 163-166
90. Braun AR, Balkin TJ, Wesenten NJ, Carson RE, Varga M, Baldwin P, Selbie S, Belenky G, Herscovitch P (1997) Regional cerebral blood flow throughout the sleep-wake cycle. An H2 15O PET study. Brain 120: 1173-1197
91. Braun AR, Balkin TJ, Wesensten NJ, Gwadry F, Carson RE, Varga M, Baldwin P, Belenky G, Herscovitch P (1998) Dissociated pattern of activity in visual cortices and their projections during human rapid eye movement sleep. Science 279: 91-95
92. Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Babler A, Vogel H, Hell D (1998) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9: 3897-3902
93. Vollenweider FX, Geyer MA (2001) A systems model of altered consciousness: integrating natural and drug-induced psychoses. Brain Res Bull 56: 495-507
94. Cancelli I, Marcon G, Balestrieri M (2004) Factors associated with complex visual hallucinations during antidepressant treatment. Hum Psychopharmacol 19: 577-584
95. Kumagai R, Ohnuma T, Nagata T, Arai H (2003) Visual and auditory hallucinations with excessive intake of paroxetine. Psychiatry Clin Neurosci 57: 548-549
96. Manford M, Andermann F (1998) Complex visual hallucinations. Clinical and neurobiological insights. Brain 121: 1819-1840
97. Ranen NG, Pasternak RE, Rovner BW (1999) Cisapride in the treatment of visual hallucinations caused by vision loss: The Charles Bonnet syndrome. Am J Geriatr Psychiatry 7: 264-266
98. Hobson JA, Pace-Schott EF (1999) Reply to Solms, Braun and Reiser. Neuropsychoanalysis 1: 206-224
99. Solms M (1997) The neuropsychology of dreams: A clinico-anatomical study. Lawrence Erlbaum Associates, Mahwah
100. Nielsen TA (1999) Mentation during sleep: The NREM/REM distinction. In: R Lydic, H Baghdoyan (eds): Handbook of behavioral state control: Molecular and cellular mechanisms. CRC Press, Boca Raton, 101-128
101. Nielsen TA (2000) A review of mentation in REM and NREM sleep: "covert" REM sleep as a possible reconciliation of two opposing models. Behav Brain Sci 23: 851-866; discussion 904-1121
102. Robbins TW, Clark L, Clarke H, Roberts AC (2006) Neurochemical modulation of orbitfrontal cortex function. In: DH Zald, SL Rauch (eds): The Orbitofrontal Cortex. Oxford University Press, Oxford, 393-422
103. Korte SM, Koolhaas JM, Wingfield JC, McEwen BS (2005) The Darwinian concept of stress: Benefits of allostasis and costs of allostatic load and the trade-offs in health and disease. Neurosci Biobehav Rev 29: 3-38
104. Nofzinger EA, Buysse DJ, Germain A, Carter C, Luna B, Price JC, Meltzer CC, Miewald JM, Reynolds CF 3rd, Kupfer DJ (2004) Increased activation of anterior paralimbic and executive cortex from waking to rapid eye movement sleep in depression. Arch Gen Psychiatry 61: 695-702
105. Maquet P, Ruby P, Maudoux A, Albouy G, Sterpenich V, Dang-Vu T, Desseilles M, Boly M, Perrin F, Peigneux P et al (2005) Human cognition during REM sleep and the activity profile within frontal and parietal cortices: A reappraisal of functional neuroimaging data. Prog Brain Res 150: 219-227
106. Pace-Schott EF (2007) The frontal lobes and dreaming. In: D Barrett, P McNamara (eds): The new science of dreaming. Praeger, Greenwood Press, Westport, 115-154
107. Goodenough DR (1991) Dream recall: history and current status of the field. In: SJ Ellman, JS Antrobus (eds): The mind in sleep. Wiley, New York, 143-171
108. Trzepacz PT (2000) Is there a final common neural pathway in delirium? Focus on acetylcholine and dopamine. Semin Clin Neuropsychiatry 5: 132-148
109. Ashton H (2002) Delirium and hallucinations. In: E Perry, H Ashton, A Young (eds): Neurochemistry of consciousness: transmitters in mind. John Benjamin, Amsterdam, 181-203
110. Dugovic C (2001) Role of serotonin in sleep mechanisms. Rev Neurol (Paris) 157: S16-19
111. Erlandsson K, Sivananthan T, Lui D, Spezzi A, Townsend CE, Mu S, Lucas R, Warrington S, Ell PJ (2005) Measuring SSRI occupancy of SERT using the novel tracer [123I]ADAM: A SPECT validation study. Eur J Nucl Med Mol Imaging 32: 1329-1336
112. Klein N, Sacher J, Geiss-Granadia T, Attarbaschi T, Mossaheb N, Lanzenberger R, Potzi C, Holik A, Spindelegger C, Asenbaum S et al (2006) In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram. Psychopharmacology (Berl) 188: 263-272
113. Ogden RT, Ojha A, Erlandsson K, Oquendo MA, Mann JJ, Parsey RV (2007) In vivo quantification of serotonin transporters using [(11)C]DASB and positron emission tomography in humans: modeling considerations. J Cereb Blood Flow Metab 27: 205-217
114. Parsey RV, Ojha A, Ogden RT, Erlandsson K, Kumar D, Landgrebe M, Van Heertum R, Mann JJ (2006) Metabolite considerations in the in vivo quantification of serotonin transporters using 11C-DASB and PET in humans. J Nucl Med 47: 1796-1802